Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients A Randomized, Double-Blind, Cross-Over Trial 英文参考文献.docVIP

下载本文档

5
0
约3.52万字
约 7页
2017-05-11 发布于上海
举报
版权申诉

Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients A Randomized, Double-Blind, Cross-Over Trial 英文参考文献.doc

1、本文档共7页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients A Randomized, Double-Blind, Cross-Over Trial 英文参考文献

EffectsofaFlaxseed-DerivedLignanSupplementinType 2DiabeticPatients:ARandomized,Double-Blind,Cross- OverTrial AnPan1,JianqinSun2,YanqiuChen2,XingwangYe1,HuaixingLi1,ZhijieYu1,YanfangWang1,WenjiaGu1,XinyiZhang2,XiafeiChen2 ,Wendy Demark-Wahnefried3,YongLiu1,XuLin1* 1KeyLaboratoryofSystemsBiology,InstituteforNutritionalSciences,ShanghaiInstitutesforBiologicalSciences,ChineseAcademyofSciencesand GraduateSchooloftheChineseAcademyofSciences,Shanghai,China,2HuadongHospital,FudanUniversity,Shanghai,China,3UniversityofTexas- MDAndersonCancerCenter,Houston,Texas,UnitedStatesofAmerica Background.Flaxseedconsumptionhasbeenshowntoimprovebloodlipidsinhumansandflaxseed-derivedlignanhasbeen shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal Findings.Thiswasarandomized,double-blind,placebo-controlled,cross-overtrialanditwasconductedbetweenApriland December2006inShanghai,China.Seventy-threetype2diabeticpatientswithmildhypercholesterolemiawereenrolledinto the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360mg lignan per day) or placebo for 12weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.1060.65 % vs. 0.0960.52 %, P=0.001) comparedtoplacebo;however,nosignificantchangeswereobservedinfastingglucose andinsulin concentrations,insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2618.1 vs. 1.262.4mg/mL, P,0.001). Data also suggested minimal competition between li